Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor

Combination chemotherapy with gemcitabine and cisplatin (GC) is recommended as the primary treatment for advanced bladder cancer (BC). However, the benefits of this approach are limited owing to the acquisition of drug resistance. Here, we found that gemcitabine‐resistant and cisplatin‐resistant BCs...

Full description

Bibliographic Details
Main Authors: Hirofumi Yoshino, Seiya Yokoyama, Motoki Tamai, Shunsuke Okamura, Sayaka Iizasa, Takashi Sakaguchi, Yoichi Osako, Satoru Inoguchi, Ryosuke Matsushita, Yasutoshi Yamada, Masayuki Nakagawa, Shuichi Tatarano, Akihide Tanimoto, Hideki Enokida
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:FEBS Open Bio
Subjects:
bladder cancer
cisplatin resistance
gemcitabine resistance
pan‐RAS inhibitor
RAS
Online Access:https://doi.org/10.1002/2211-5463.13616

Internet

https://doi.org/10.1002/2211-5463.13616

Similar Items